title: Overexpression of AIB1 correlates inversely with E-cadherin expression in pancreatic adenocarcinoma and may promote lymph node metastasis.
abstract: BACKGROUND
  It was reported that the nuclear receptor coactivator amplified in breast cancer1 (AIB1) could regulate cancer cell invasion and migration in a nuclear receptor signaling-independent manner. Meanwhile, the process of epithelial mesenchymal transition (EMT) is critical for tumor invasion and metastasis. The present study aimed to determine the role of AIB1 and EMT markers in human pancreatic adenocarcinoma.
  
  
  METHODS
  AIB1, ZO-1, E-cadherin, vimentin, and N-cadherin protein expression in 76 pancreatic adenocarcinomas were assessed using immunohistochemistry and analyzed for clinicopathological significance.
  
  
  RESULTS
  The frequency of AIB1 overexpression in pancreatic adenocarcinomas with lymph node metastasis is 68 % (19/28), which is significantly higher than in pancreatic adenocarcinomas without lymph node metastasis (42 %; 20/48). In addition, the frequency of low expression of E-cadherin in pancreatic carcinomas with lymph node metastasis (68 %; 19/28) was significantly higher than in tumors without lymph node metastasis (44 %; 21/48). Correlation analysis demonstrated that the overexpression of AIB1 was inversely correlated with low expression of E-cadherin in pancreatic adenocarcinomas.
  
  
  CONCLUSIONS
  Overexpression of AIB1 might promote invasion and metastasis of cancer cells and is associated with down-regulation of E-cadherin in pancreatic adenocarcinomas.
authors.affiliation: Clinical Laboratory, Henan Provincial People's Hospital, 7 Wei Wu Road, Zhengzhou, 450000, China.
authors.forename: Si
authors.initials: S
authors.lastname: Guo
authors.forename: JingJing
authors.initials: J
authors.lastname: Xu
authors.forename: Rui
authors.initials: R
authors.lastname: Xue
authors.forename: YuQiong
authors.initials: Y
authors.lastname: Liu
authors.forename: HaiBo
authors.initials: H
authors.lastname: Yu
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry* / Q000556:secondary; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015820:Cadherins / Q000032:analysis*; D058750:Epithelial-Mesenchymal Transition; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D056921:Nuclear Receptor Coactivator 3 / Q000032:analysis*; D010190:Pancreatic Neoplasms / Q000737:chemistry* / Q000473:pathology
chemical_list: D015820:Cadherins; C538866:NCOA3 protein, human; D056921:Nuclear Receptor Coactivator 3
references.citation: Cancer. 2002 Dec 1;95(11):2346-52
references.pmid: 12436441
references.citation: Cancer Res. 2004 Mar 1;64(5):1875-85
references.pmid: 14996752
references.citation: Nat Rev Cancer. 2004 Feb;4(2):118-32
references.pmid: 14964308
references.citation: FEBS Lett. 2007 Oct 30;581(26):5075-81
references.pmid: 17927986
references.citation: Nat Rev Cancer. 2005 Jun;5(6):459-67
references.pmid: 15905855
references.citation: Cancer Res. 2007 Jun 15;67(12):5965-75
references.pmid: 17575167
references.citation: Cancer Res. 2008 Jul 1;68(13):5460-8
references.pmid: 18593949
references.citation: Nat Rev Cancer. 2002 Jun;2(6):442-54
references.pmid: 12189386
references.citation: Cancer Sci. 2009 Sep;100(9):1591-6
references.pmid: 19552757
references.citation: Cancer Lett. 2008 Mar 8;261(1):64-73
references.pmid: 18162290
references.citation: Cell Biol Toxicol. 2010 Dec;26(6):553-67
references.pmid: 20397042
references.citation: Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6134-42
references.pmid: 15448000
references.citation: Science. 1997 Aug 15;277(5328):965-8
references.pmid: 9252329
references.citation: Am J Clin Pathol. 2008 May;129(5):728-34
references.pmid: 18426732
references.citation: Nat Rev Cancer. 2009 Apr;9(4):265-73
references.pmid: 19262571
references.citation: Mol Cell Biol. 2008 Oct;28(19):5937-50
references.pmid: 18644862
references.citation: Cancer Res. 2006 Sep 1;66(17):8319-26
references.pmid: 16951136
references.citation: J Pathol. 1994 Dec;174(4):243-8
references.pmid: 7884585
references.citation: J Steroid Biochem Mol Biol. 2007 May;104(3-5):237-40
references.pmid: 17532621
references.citation: Mol Cell Endocrinol. 2005 Dec 21;245(1-2):77-85
references.pmid: 16298470
references.citation: Cancer Cell. 2004 Sep;6(3):263-74
references.pmid: 15380517
references.citation: Oncogene. 2008 Jan 31;27(6):823-30
references.pmid: 17653082
references.citation: Cancer Res. 2010 May 15;70(10):4102-11
references.pmid: 20442283
references.citation: Int J Cancer. 2000 May 20;89(3):217-23
references.pmid: 10861496
references.citation: Am J Pathol. 2010 Mar;176(3):1256-70
references.pmid: 20075196
references.citation: Am J Pathol. 2009 May;174(5):1588-93
references.pmid: 19342369
references.citation: Am J Pathol. 1999 Feb;154(2):525-36
references.pmid: 10027410
references.citation: Gastric Cancer. 2001;4(2):66-74
references.pmid: 11706763
references.citation: Int J Oncol. 2001 Mar;18(3):513-20
references.pmid: 11179480
references.citation: Oncogene. 2008 Apr 10;27(17):2430-44
references.pmid: 17968310
references.citation: Mol Cell Biol. 2003 Nov;23(21):7742-55
references.pmid: 14560019
references.citation: Lancet. 2004 Mar 27;363(9414):1049-57
references.pmid: 15051286
references.citation: Mol Cell Biol. 2002 Sep;22(18):6611-26
references.pmid: 12192059
references.citation: Br J Cancer. 2001 Dec 14;85(12):1928-36
references.pmid: 11747336